Broadwood Capital Inc Lineage Cell Therapeutics, Inc. Transaction History
Broadwood Capital Inc
- $1.26 Billion
- Q4 2024
A detailed history of Broadwood Capital Inc transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Broadwood Capital Inc holds 41,666,255 shares of LCTX stock, worth $23.3 Million. This represents 1.65% of its overall portfolio holdings.
Number of Shares
41,666,255
Previous 41,666,255
-0.0%
Holding current value
$23.3 Million
Previous $37.9 Million
45.05%
% of portfolio
1.65%
Previous 2.94%
Shares
3 transactions
Others Institutions Holding LCTX
# of Institutions
135Shares Held
106MCall Options Held
22.1KPut Options Held
0-
Black Rock Inc. New York, NY9.56MShares$5.35 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$4.83 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$4.05 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$3.34 Million1.17% of portfolio
-
Raffles Associates LP New York, NY5.49MShares$3.08 Million3.26% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $95.1M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...